



August 12, 2020

BSE Limited,
Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001.

✓ **National Stock Exchange of India Ltd.,**
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations).

Pursuant to Regulation 30(2) read with Para A(7) of Part A of Schedule III of the Listing Regulations, we wish to inform you that the Board of Directors at its meeting held today i.e. Wednesday, August 12, 2020, appointed Mr. K. B. S. Anand (DIN: 03518282) and Dr. Punita Kumar Sinha (DIN: 05229262) as Independent Directors of the Company for a period of five years i.e. from August 12, 2020 to August 11, 2025.

Enclosed is a Press Release for the above.

Thanking you,

Yours faithfully,
For **LUPIN LIMITED**

R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)



Encl.: a/a

Mr. K.B.S. Anand and Dr. Punita Kumar-Sinha Join Lupin Board as Independent Directors

Mumbai, India, August 12, 2020: Pharma major Lupin Limited (Lupin) announced today the appointment of Mr. K.B.S. Anand and Dr. Punita Kumar-Sinha as Independent Directors.

Mr. K.B.S. Anand most recently served as Managing Director and Chief Executive Officer at Asian Paints, India's leading paint company. With a career spanning over four decades at Asian Paints, Mr. Anand worked across manufacturing, sales and marketing functions. He was nominated as the 'Best CEO - Private Sector' at the Forbes Leadership Awards in 2016 and was awarded the Qimpro Gold Standard in Business for Quality in 2017. He currently serves as an Independent Director on the Board of Marico, Tata Chemicals and Borosil.

Mr. Anand holds a B. Tech in Mechanical Engineering from Indian Institute of Technology (IIT), Mumbai, and a PGDM from Indian Institute of Management (IIM), Kolkata.

Dr. Punita Kumar-Sinha brings significant governance and investment experience across India and North America. In her three decade career, she pioneered some of the first foreign investments into the Indian equity markets in the early 1990s. She founded Pacific Paradigm Advisors, an independent investment advisory and management firm, and was formerly a Senior Managing Director at Blackstone. She serves as an Independent Director for several companies including Infosys, JSW Steel, Blackstone Embassy REIT and Rallis. Dr. Kumar-Sinha is also on the Board of Governors of the CFA Institute (the premier global association for investment management professionals) and has been awarded the Distinguished Alumni Award from Indian Institute of Technology (IIT), New Delhi.

Dr. Kumar-Sinha holds a PhD and a Master's in Finance from the Wharton School, University of Pennsylvania. She received her B. Tech in Chemical Engineering with Distinction from Indian Institute of Technology (IIT), New Delhi. She is a CFA charter holder, a TiE Charter Member, and a member of the Council on Foreign Relations.

Commenting on the appointment, **Manju D. Gupta, Chairman, Lupin** said, "We are delighted to welcome Mr. K.B.S. Anand and Dr. Punita Kumar-Sinha to our board. With their long and illustrious careers, they bring decades of experience in key areas such as innovation, strategy, capital markets and financial expertise that are crucial to Lupin's future operations and strategy".

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions and in India by global revenues. The Company invests 9.6 % of its revenues on research and development.

Lupin has fifteen manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

Please visit www.lupin.com for more information.

Follow us on Twitter: www.twitter.com/LupinGlobal | LinkedIn: www.linkedin.com/company/lupin/

| Facebook: www.facebook.com/LupinWorld/

For further information or queries please contact –

<p>Arvind Bothra Head – Investor Relations and Corporate Communications Email: arvindbothra@lupin.com Tel: +91 22 6640 8237</p>	<p>Manjira Sharma General Manager – Corporate Communications Email: manjirasharma@lupin.com Tel: +91 22 6640 2532</p>
--	---